Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:28 AM
Ignite Modification Date:
2025-12-25 @ 2:28 AM
NCT ID:
NCT07030634
Eligibility Criteria:
Inclusion Criteria:
* Participants will be selected from both sexes.
* Participants BMI will be between 18 and 24.9 (Kg/m²).
* Dominant or non-dominant lower limb .
* Grade I, and II recurrent ankle sprain patients .
* Participants self-reported a history of at least one significant lateral ankle sprain (LAS) greater than 12 months prior to testing, and recurring ankle sprains, ankle "giving way," and/or "feelings of instability."
* Participant will have unilateral recurrent ankle sprain
Exclusion Criteria:
* A history of previous surgeries to the musculoskeletal structures (ie, bones, joint structures, nerves) in either limb of the lower extremity.
* A history of a fracture in either limb of the lower extremity requiring realignment .
* Acute injury to musculoskeletal structures of other joints of the lower extremity in the previous 3 months, which impacted joint integrity and function (ie, sprains, fractures) resulting in interruption of desired physical activity .
* Hip joint or, Knee joint replacement .
* Patients possibly at risk of adverse reactions of blood flow restriction are those with poor circulatory system, obesity, diabetes, arterial calcification, sickle cell trait, severe hypertension, or renal compromise
* Any neurological conditions which affect proprioception such as polyneuropathy, multiple sclerosis, and sensory ataxia .
* Vestibular deficits, and vision problems .
* Pregnancy.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
30 Years
Study:
NCT07030634
Study Brief:
Protocol Section:
NCT07030634